

PRECEPTORSHIP PROGRAMME

Prostate Cancer

Multidisciplinary management,
standards of care, therapeutic targets
and future perspectives

**ESMO VIRTUAL
PRECEPTORSHIP**

28 OCTOBER 2021

Co-Chairs

Karim Fizazi, France

Silke Gillissen, Switzerland

ESMO VIRTUAL PRECEPTORSHIP PROGRAMME PROSTATE CANCER

Multidisciplinary management, standards of care,
therapeutic targets and future perspectives

28 October 2021

CO-CHAIRS: Karim Fizazi, France
Silke Gillissen, Switzerland

SPEAKERS: Elena Castro, Spain
Eva Comperat, Austria
Theo M. de Reijke, Netherlands
Alberto Bossi, France
Anne-Laure Giraudet, France

LEARNING OBJECTIVES

- To learn about fundamentals of epidemiology, natural history and diagnosis as contributing factors to heterogeneity in prostate cancer
- To understand essentials in the assessment and multidisciplinary treatment of prostate cancer
- To learn about advances in treatment and novel targets in prostate cancer

ACCREDITATION

The programme of this event has been accredited with **5 ESMO-MORA category 1 points**.
Recertification is necessary for medical oncologists to remain professionally certified by ESMO. Recertification guarantees that a certified medical oncologist has continued to update her/his knowledge and continues to possess the necessary skills and standards for the practice of medical oncology. For further details, please refer to esmo.org.

ACKNOWLEDGEMENTS

This event is supported by an unrestricted educational grant from



ORGANISATION AND CONTACTS

ESMO Head Office
Education Department
Via Ginevra 4
6900 Lugano
Switzerland
Email: courses@esmo.org
www.esmo.org



All timings are to be considered CEST (Central European Summer Time)

Thursday, 28 October 2021

09:00-09:05 05'	Opening and welcome	
05'	Welcome from ESMO - Objectives and scientific introduction	Karim Fizazi, FR Silke Gillessen, CH
09:05-10:15 70'	SESSION 1 Screening, diagnosis, staging and localized prostate cancer	Moderators: Silke Gillessen, CH and Karim Fizazi, FR
15'	PSA screening, diagnosis and staging classification	Theo M. de Reijke, NL
15'	Pathological diagnosis for the clinician (including variants of PCa)	Eva Comperat, AT
20'	Treatment of localized prostate cancer according to risk category (including pathological variants)	Theo M. de Reijke, NL
10'	Discussion	Faculty and all
10'	Case presentation localised prostate cancer	Participant
10:15-10:30	Break	
10:30-12:00 90'	SESSION 2 Systemic treatment and metastatic disease	Moderators: Silke Gillessen, CH and Karim Fizazi, FR
20'	ADT and other hormonal treatments, mechanisms of action, main efficacy results and toxicities	Silke Gillessen, CH
20'	Chemotherapy (taxanes and platins) and Radium-223, mechanism of action, main efficacy results in Castration-Resistant Prostate Cancer (CRPC) and toxicities	Elena Castro, ES
15'	Bone health agents, mechanism of action, efficacy and toxicities	Karim Fizazi, FR
15'	Molecular characterisation: Germline and somatic testing	Elena Castro, ES
10'	Discussion	Faculty and all
10'	Case presentation advanced prostate cancer	Participant
12:00-14:00	Break	
14:00-15:30 90'	SESSION 3 Castration-sensitive prostate cancer	Moderators: Silke Gillessen, CH and Karim Fizazi, FR
15'	Rising PSA and detectable PSA after radical local treatment: Prognosis, indications for salvage local treatments, adjuvant vs salvage treatments	Alberto Bossi, FR
20'	Use of early vs deferred systemic treatments in biochemical failures and in M0 CRPC	Karim Fizazi, FR
20'	Metastatic castration-sensitive prostate cancer (mCSPC)	Silke Gillessen, CH
15'	Oligo-metastatic treatment: what treatment?	Alberto Bossi, FR
10'	Discussion	Faculty and all
10'	Case presentation advanced prostate cancer	Participant

15:30-15:45	Break	
15:45-17:05 80'	SESSION 4 Metastatic castration-resistant disease	Moderators: Silke Gilllessen, CH and Karim Fizazi, FR
20'	PARP inhibitors and experimental treatments for mCRPC	Karim Fizazi, FR
20'	PSMA in diagnostic and therapy	Anne-Laure Giraudet, FR
20'	Metastatic CRPC: Current treatment	Silke Gilllessen, CH
10'	Discussion	Faculty and all
10'	Case presentation metastatic prostate cancer	Participant
17:05-17:10 05'	Conclusion and farewell	Karim Fizazi, FR Silke Gilllessen, CH

Note: Each 10 minutes slot for clinical case discussion includes 5' case presentation and 5' Q&A/panel discussion